Axcan Pharmaceuticals (AXP.TO)
Financials 
Technical Analysis 0
TOP PICK
Part pharmaceutical and part drug development. Very profitable. Strong balance sheet and lots of cash flow. Generates about US$1.50 free cash flow every year. In a very stable gastro-intestinal market. They're also in-licence some drugs which gives them some pretty good upside. Trading at about US$14 with $1 a share free cash on the balance sheet.
Chris FernycOwned
biotechnologypharmaceutical
TOP PICK
A very focused (gastro intestinal) pharmaceutical company and as a result, it is very profitable. You pretty well get a free call option on a potentially block-buster drug called Itax. Huge market in North America.
Fred PynnOwned
biotechnologypharmaceutical
TOP PICK
Last news was that R&D spending would be higher than the street anticipated. Launching a product that could be a $200 million product.
Danny TomkaOwned
biotechnologypharmaceutical
TOP PICK
The entire US financial sector is attractive. Their brokerage sector is growing rapidly. Expects travel business will pick up.
John Sinkins, CFAOwned
biotechnologypharmaceutical
Showing 1 to 9 of 9 entries
- «
- ‹
- 1
- ›
- »
Axcan Pharmaceuticals (AXP.TO) Frequently Asked Questions
What is Axcan Pharmaceuticals stock symbol?
Axcan Pharmaceuticals is a OTC stock, trading under the symbol AXP.TO (previously AXP-T on Stockchase) on the (). It is usually referred to as or AXP.TO
Is Axcan Pharmaceuticals a buy or a sell?
In the last year, there was no coverage of Axcan Pharmaceuticals published on Stockchase.
Is Axcan Pharmaceuticals a good investment or a top pick?
Axcan Pharmaceuticals was recommended as a Top Pick by Ed Ho on 2000-12-11. Read the latest stock experts ratings for Axcan Pharmaceuticals.
Why is Axcan Pharmaceuticals stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for help on deciding if you should buy, sell or hold the stock.
Is Axcan Pharmaceuticals worth watching?
In the last year 0 stock analysts on Stockchase covered Axcan Pharmaceuticals. The stock is worth watching.
